Amgen remains first and alone on the US aflibercept biosimilar market, but a West Virginia court has narrowed most of its defenses against Regeneron’s latest patent case.
Amgen remains first and alone on the US aflibercept biosimilar market, but a West Virginia court has narrowed most of its defenses against Regeneron’s latest patent case.